الفهرس | Only 14 pages are availabe for public view |
Abstract Antiphospholipid antibodies (aPL ) namely anticardiolipin antibodies (aCL ) and lupus anticoagulant ( LAC ) have been associated with an increased risk of thrombosis in systemic lupus erythematosus ( SLE ) . We examined additional thrombosis risk factors ( aPL profile , SLE - related and traditional risk factors ) and the primary thrombsis prevention in SLE patients with and without aPL |